Content area


Glukagonlignende peptid 1-receptoragonister til behandling af type 2-diabetes

Andreas Andersen1, Alexander Sidelmann Christensen1, Filip Krag Knop1, 2, 3 & Tina Vilsbøll1, 2
1) Klinisk Metabolisk Fysiologi, Steno Diabetes Center Copenhagen 2) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 3) Novo Nordisk Foundation Center for Basic Metabolic Research, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet

Ugeskr Læger 2019;181:V10180725
Ugeskr Læger 2019;181:V10180725

Andreas Andersen, Alexander Sidelmann Christensen, Filip Krag Knop & Tina Vilsbøll:

Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes

Ugeskr Læger 2019;181:V10180725

Supraphysiological levels of the incretin hormone glucagon-like peptide 1 (GLP-1) have demonstrated a marked glucose-lowering effect in patients with Type 2 diabetes. Six GLP-1 receptor agonists are currently available for the treatment of Type 2 diabetes and have all proven to render significant reductions in both glycated haemoglobin level and body weight. However, of the clinical available compounds only liraglutide, dulaglutide and semaglutide have demonstrated reductions in the risk of cardiovascular disease. This review aims at providing an overview of the efficacy and safety of the GLP-1 receptor agonist class.

Du skal være logget ind for at læse denne artikel
Log ind

Right side